Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.

Abstract

BACKGROUND:

To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment.

METHODS:

This study retrospectively evaluated 202 patients with locally advanced ESCC treated at Shandong Cancer Hospital between January 2009 and December 2013. All the patients initially received dCRT, including platinum and paclitaxel or 5-fluorouracil, with concurrent 1.8 or 2 Gy/fraction radiation (total dose, 54-60 Gy). The patient population was divided into two treatment groups: 105 patients who received the cisplatinum/paclitaxel regimen were allocated to group A, and 97 patients who received the cisplatinum/5-fluorouracil regimen were allocated to group B. We compared the progression-free survival (PFS) and overall survival (OS) by various clinical variables, including prior treatment characteristics, major toxicities (mainly in grade 3 and 4 hematological), and response to dCRT. We used the receiver operating curve analysis to determine the optimal cutoff value of clinical stage and radiation dose. The Kaplan-Meier method was used for survival comparison and Cox regression for multivariate analysis.

RESULTS:

Median PFS and OS in group A were significantly better compared with group B (median PFS, 15.9 versus 13.0 months, P=0.016 and median OS, 33.9 versus 23.1 months, P=0.014, respectively). The 1- and 2-year survival rates of the two groups were 82.9% versus 76.3%, and 61.9% versus 47.6%, respectively. The complete response and response rate were 17.1% versus 7.2% (P=0.032) and 52.4% versus 30.9% (P=0.042) in group A and B, respectively. Meanwhile, group B was associated with a significantly lower rate of grade 3/4 overall toxicity than group A (P=0.039).

CONCLUSION:

Our data showed that patients with locally advanced ESCC in group A had longer PFS and OS compared with group B. Cisplatinum/paclitaxel can be considered a good candidate chemotherapy regimen for patients with locally advanced ESCC who are being treated with nonsurgical therapy.

• Authors: Guofang Hu, Zhehai Wang, Yuan Wang, Qingqing Zhang, Ning Tang, Jun Guo, Liyan Liu, Xiao Han
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 10 Pg. 2129-36 ( 2016) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 27445460 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Paclitaxel
• Cisplatin
• Fluorouracil

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Carcinoma, Squamous Cell (diagnosis, drug therapy, therapy)
• Chemoradiotherapy
• Cisplatin (administration & dosage, adverse effects, therapeutic use)
• Esophageal Neoplasms (diagnosis, drug therapy, therapy)
• Esophageal Squamous Cell Carcinoma
• Female
• Fluorouracil (administration & dosage, adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Paclitaxel (administration & dosage, adverse effects, therapeutic use)
• Retrospective Studies
• Survival Rate
• Young Adult